



TopGum
Innovation you can taste

Q2 2025

August 26, 2025



LEGAL DISCLAIMER

The information included under this presentation (the “Presentation”) is for informational purposes only and does not constitute or form any part of any offer to purchase securities and/or an invitation to make offers for their purchase or solicitation of any of the above regarding any securities of Top Gum Industries Ltd. (the “**Company**”) and should not be regarded as a recommendation or an opinion. Any such offer or sale will be made on the basis of a prospectus published by the Company after receiving a permit from the Securities Authority and approval from the Tel Aviv Stock Exchange (hereinafter, respectively: “**Securities Authority**” and “**the Stock Exchange**”).

This presentation does not purport to encompass or contain any information that may be relevant for the purpose of making any decision regarding an investment in the Company's securities and generally. This presentation does not replace independent data collection and analysis, it should be bear in mind that past data does not necessarily indicate future performance. The presentation includes data and statistics and other publications published by third parties, the content of which has not been independently verified by the Company. The presentation was made, for a convenient and concise presentation, and it does not exhaust the full data about the company and its activities and does

not replace the need to perform a full due diligence. The information contained in this presentation is incomplete and all that is stated in it is subject to a full due diligence and is not a substitute for reviewing reports published by the Company to the public and especially in the draft prospectus or final company prospectus, supplementary prospectus and shelf prospectus. The information under this Presentation is not a substitute for public Information and in the event of any conflict between the content of this presentation and the content of any public Information, the content of the Public Information shall prevail. The information in this Presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be made on the fairness, accuracy, completeness or correctness of the information or opinions contained herein. No legally binding obligations may be created, implied, or inferred from this Presentation. Various statements in this presentation include information which derives from forecasts, estimates, assessments, and other information pertaining to future events and/or matters, the materialization of which is uncertain and beyond the Company's control, and which constitute “forward-looking information”, as defined under the Israeli Securities Law, 1968. Forward-looking statements include descriptions regarding the intent,

belief, or current expectations of the Company and are not guaranteeing future results, performance, or achievements and are based on current expectations, estimations, and assumptions, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performances, or achievements of the Company may differ materially from what is or may be expressed or implied in this presentation due to a variety of factors, many of which are beyond the Company's control, including, without limitation, certain risk factors. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events, or otherwise. Certain information and factual statements (including relating to markets or trends) contained herein are based on or derived from publicly available documents or independent third-party sources, and therefore the accuracy of such information and the assumptions on which such information is based has not been independently verified. Nothing in this presentation constitutes tax or business advice and does not constitute a substitute consulting appropriate advisors in these aspects. Every potential investor should seek advice and guidance in connection with potential investments, including tax advice is given such investor tax status.

Q2 2025 HIGHLIGHTS

Best Ever
Supplements Q2
USD 17.8M;
79% of Total Sales;
+69% QoQ

All-Time
Revenue Record
USD 22.6M;
+51% QoQ

Institutional
Investors Stock
Option Exercise
~USD 6.8M



Adjusted
EBITDA
USD 3.5M;
+35% QoQ

Capital Raising
~ USD 28M
(ILS 100M)



Q2 2025 CONTINUES OUR STRONG REVENUE GROWTH OF SUPPLEMENTS SALES


USD M



Supplements Confectionary & Others

STRONG SUPPLEMENTS PERFORMANCE


Our strategic shift from a local confectionary manufacturer to a global supplement leader continues



PROFITABLE GROWTH

SOLID AND CONTINUOUS EBITDA (ADJ.) IMPROVEMENT

USD M




RECORD BACKLOG

- A continued strong increase in year-over-year customers' orders backlog of dietary supplements



Customers' Orders Backlog (USD M)



The background is a solid teal color. It features several large, overlapping circles in a slightly darker shade of teal. In the top-left corner, there is a cluster of chocolate-covered almonds. Another single chocolate-covered almond is positioned just above the text circle.

STRATEGIC PIVOTS

OUR TRANSFORMATIONAL PIVOTS

From

To

Confectionery



Supplements

Generic product



Tailor made

Local



International

Limited innovation




Innovation leader






FROM CONFECTIONARY TO SUPPLEMENTS

Our strategic shift from a local confectionary leader to a global supplement pioneer continues to gain momentum



SHIFT TOWARDS UNIQUE SOLUTIONS CONTINUES, WHILE KEEPING A SOLID SHARE OF OFF-SHELF PRODUCTS



USD M



EXPANDING OUR GLOBAL REACH

All regions experience significant growth in the last few of years

USD M




FROM LOCAL TO GLOBAL

In the last four years TopGum has continuously expanded its presences worldwide

2020



2025



INNOVATIVE DELIVERY SYSTEM

Highest standards of nutraceuticals in the industry



Differentiated Matrix

GUMMICEUTICALS™

Truly sugar-free/No-added sugar | Prebiotic effect
Organic (fiber or sugar based) | Unique fibers matrix

Organoleptic Experience

Flavor | Color | Texture | Odor | Shape
High-resistance melting point
Clean label ingredients

High Dosage

Highest dosage per one gummy
without affecting the flavor
Awarded winning products


Improved Functionality

Micro-encapsulation
Masks flavors | Slow-release | Improves stability | Targeted release
Enables new active ingredients | Preserves potency



Microencapsulation Applications

Proprietary technology using unique formulas and know-how



Targeted absorption



Controlled release profile



Masking flavors & taste




Improved stability



Multi Layer Coating

Active ingredient

NEW FACILITY IN FINAL STAGES



 TopGum

**Save
the
date**

**18.09.25
11:00**

אירוע השקת המפעל החדש
של TOPGUM
אזור תעשייה שער הנגב

פרטים נוספים בהמשך



TOPGUM CANADA POST-ACQUISITION STATUS



ISLAND ABBEY
NUTRITIONALS™

- PMI in full steam, with all functional integration streams in process
- North American commercial operations consolidated under Dean Williams, CEO of Island Abbey
- Synergies realization started in all identified strategic areas

P&L

USD thousands

	Q2 2025	Q2 2024	QoQ Change
Revenue	22,573	14,992	7,581
Cost of sales	15,603	9,615	5,988
Gross profit	6,970	5,377	1,593
% from sales	30.9%	35.9%	-5.0%
R&D	1,214	760	454
S&M	2,035	1,100	935
G&A	2,138	1,887	251
Other (income)/expenses	1,727	0	1,727
Operating profits	-144	1,630	-1,774
% from sales	-0.6%	10.9%	-11.5%
Finance expenses (Income), net	-4,110	122	-4,232
Profit before tax	3,966	1,508	2,458
Tax expenses	921	265	656
Net profits	3,045	1,243	1,802
EBITDA	2,965	2,216	749
Adjusted EBITDA	3,509	2,596	913
% from sales	15.5%	17.3%	-1.8%

Non-GAAP EBITDA excludes one-time expenses from ESOP grants and bonuses to employees regarding IPO / Equity transactions

SOLID FINANCIAL STRENGTH

USD thousands

	30.06.2025	30.06.2024
Assets		
Currents assets	58,210	49,230
Non-current assets	104,974	62,077
Total assets	163,184	111,307
Liabilities		
Current liabilities	51,951	18,827
Non-current liabilities	33,122	23,946
Total liabilities	85,073	42,773
Equity		
Share capital	3,170	3,071
Share premium	64,114	56,797
Capital reserves	4,706	-2,218
Retained earnings	6,121	10,884
Total equity	78,111	68,534
Total liabilities and equity	163,184	111,307



Thank you